Inicio / Gastroenterología / Abstracts de gastroenterología / Clinical impact of intratumoral HER2 heterogeneity on trastuzumab efficacy in patients with HER2-positive gastric cancer

Clinical impact of intratumoral HER2 heterogeneity on trastuzumab efficacy in patients with HER2-positive gastric cancer

0 / 5 (0 votos)
Clinical impact of intratumoral HER2 heterogeneity on trastuzumab efficacy in patients with HER2-positive gastric cancer

Journal of Gastroenterology

Fecha de publicación:  09 de abril de 2018

DOI: https://doi.org/10.1007/s00535-018-1464-0

Autores: Takeru Wakatsuki, Noriko Yamamoto, Takeshi Sano, Keisho Chin, Hiroshi Kawachi, Daisuke Takahari, Mariko Ogura, Takashi Ichimura, Izuma Nakayama, Hiroki Osumi, Tomohiro Matsushima, Mitsukuni Suenaga, Eiji Shinozaki, Naoki Hiki, Yuichi Ishikawa, Kensei Yamaguchi.

Background: There is growing interest in the clinical significance of intratumoral HER2 heterogeneity. Its prognostic and predictive impacts on trastuzumab efficacy were demonstrated in breast cancer. However, its clinical significance in gastric cancer is still unclear.

SEGUIR LEYENDO

Comentarios

Para dejar un comentario antes debes iniciar sesión:

¿No tienes una cuenta?

Regístrate a través de éste enlace.